Citations

Clear

400 citation(s) found for "Berry, DA".

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Fernández-Martínez, Aranzazu , Krop, Ian E. , Hillman, David W. , Polley, Mei‐Yin C. , Huebner, Lucas J. , Hoadley, Katherine A. , Shepherd, Jonathan H. , Tolaney, Sara M. , Henry, N. Lynn , Dang, Chau T. , Harris, Lyndsay N. , Berry, Donald A. , Hahn, Olwen, Hudis, Clifford A. , Perou, Charles M. , Polley, Mei-Yin , Huebner, Lucas , Hoadley, Katherine A , Tolaney, Sara , Henry, N Lynn , Berry, Donald , Hudis, Clifford , Winer, Eric , Partridge, Ann H , Perou, Charles M , Hillman, David W , Parker, Joel S. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A. , Shepherd, Jonathan H. , Fernandez-Martinez, Aranzazu

Mayo Clinic

Journal of Clinical Oncology | October 23, 2020 | Volume: 38 | Issue: 35 | Pages: 4184-4193

10.1200/jco.20.01276 | PMID 33095682 Get It

PURPOSE CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
Impact of exposure to patients with COVID-19 on residents and fellows: an international survey of 1420 trainees
Cravero, Anne , Kim, Nicole J. , Feld, Lauren D. , Rabiee, Atoosa , Bazarbashi, Najdat , Bassin, Sandhya R. , Lee, Tzu-Hao, Moon, Andrew M. , Liang, Peter S. , Aby, Elizabeth S. , Khan, Mohammad Qasim , Young, Kristen , Kobeissy, Abdallah, Hashim, Almoutaz, Houser, Allysia, Ioannou, George N. , Cravero, Anne L , Young, Kristen J , Liang, Peter S , Moon, Andrew M , Berry, Kristin , Qi, Xiaolong , Patel, Arpan , Wijarnpreecha, Karn , Khan, Mohammad Qasim

Mayo Clinic

Postgraduate Medical Journal | October 21, 2020 | Volume: 97 | Issue: 1153 | Pages: 706-715

10.1136/postgradmedj-2020-138789 | PMID 33087533 Get It

ABSTRACTObjectivesTo determine how self-reported level of exposure to patients with novel coronavirus 2019 (COVID-19) affected the perceived safety, training and well-being of residents and fellows.MethodsWe administered an anonymous, voluntary, web-based survey to a convenience sample of trainees worldwide. The survey was distributed by email and social media posts from April 20th to May 11th, 2020. Respondents were asked to estimate the number of patients with COVID-19 they cared for in March and April 2020 (0, 1–30, 31–60, >60). Survey questions addressed (1) safety and access to personal protective equipment (PPE), (2) training and professional development and (3) well-being and burnout.ResultsSurveys were completed by 1420 trainees (73% residents, 27% fellows), most commonly from the USA (n=670), China (n=150), Saudi Arabia (n=76) and Taiwan (n=75). Trainees who cared for a greater number of patients with COVID-19 were more likely to report limited access to PPE and COVID-19 testing and more likely to test positive for COVID-19. Compared with trainees who did not take care of patients with COVID-19 , those who took care of 1–30 patients (adjusted OR [AOR] 1.80, 95% CI 1.29 to 2.51), 31–60 patients (AOR 3.30, 95% CI 1.86 to 5.88) and >60 patients (AOR 4.03, 95% CI 2.12 to 7.63) were increasingly more likely to report burnout. Trainees were very concerned about the negative effects on training opportunities and professional development irrespective of the number of patients with COVID-19 they cared for.ConclusionExposure to patients with COVID-19 is significantly associated with higher burnout rates in physician trainees.
Intermediate to Long-Term Follow-up of Cementing Liners into Well-Fixed Acetabular Components
Bedard, Nicholas A. , Tetreault, Matthew W. , Hanssen, Arlen D. , Lewallen, David G. , Trousdale, Robert T. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Berry, Daniel J , Bedard, Nicholas A

Mayo Clinic

Journal of Bone and Joint Surgery | September 8, 2020 | Volume: 102 | Issue: 16 | Pages: 1397-1404

10.2106/jbjs.19.01441 | PMID 32816416 Get It

Background: The cementation of a new liner into a well-fixed acetabular component is common during revision total hip arthroplasty (THA) for many indications, but most commonly for lack of a modern, compatible, highly cross-linked polyethylene (HXLPE) liner. However, little is known about the intermediate-term to long-term durability of this strategy. The purpose of this study was to evaluate the implant survivorship, risk of complications, clinical outcomes, and radiographic results of cementing a new HXLPE liner into a well-fixed acetabular component. Methods: We retrospectively identified 323 revision THAs in which a nonconstrained HXLPE liner was cemented into a well-fixed acetabular component. The mean age at the time of the revision THA was 63 years, and 50% of patients were female. The most common indications for revision THA were polyethylene wear and osteolysis (48%), aseptic femoral loosening (35%), and hip instability (8%). The mean follow-up was 9 years. Results: Polyethylene liner failure occurred in 11 cases (3%). In all cases, the cemented liner dissociated from the acetabular component. At 10 years, the survivorship free from any revision was 80% (95% confidence interval [CI], 75% to 84%) and the survivorship free from any reoperation was 77% (95% CI, 72% to 82%). The most common reason for re-revision was dislocation (45% of reoperations). A dislocation occurred in 17% of cases. Hips that underwent revision for instability were significantly more likely to dislocate compared with hips that underwent revision for liner wear (hazard ratio [HR], 2.3 [95% CI, 1.2 to 4.5]; p = 0.02). Elevated rim or face-changing liners were significantly more likely to dissociate than flat liners (HR, 9.0 [95% CI, 1.2 to 70.6]; p = 0.04). Conclusions: Cementation of a nonconstrained HXLPE liner into a well-fixed acetabular component during revision THA provided durable fixation with only a small number of failures at the cement interface (3%). Instability after this procedure remains a concern, but this is multifactorial in nature. These data support the continued use of this technique, when necessary, during revision THA. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Haddad, Tufia C. , Stringer-Reasor, Erica , Chien, A. Jo , Borges, Virginia, Nanda, Rita , Albain, Kathy S. , Müller, Aixa , Kemmer, Kathleen, Clark, Amy S. , Perlmutter, Jane , Melisko, Michelle , Schwab, Richard B. , Wilson, Amy , Singhrao, Ruby , Asare, Smita , Veer, Laura J. van’t , Sanil, Ashish, Berry, Donald A. , Pusztai, Lajos , Han, Hyo S , Yau, Christina , Wolf, Denise M. , Wallace, Anne M. , Shatsky, Rebecca , Helsten, Teresa L. , Boughey, Judy C. , Falkson, Carla I. , Mukhtar, Rita A. , Elias, Anthony , Yee, Douglas , Kalinsky, Kevin M. , Isaacs, Claudine , Thomas, Alexandra , Hylton, Nola M. , Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT011-CT011

10.1158/1538-7445.am2020-ct011 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint risk to evaluate novel agents as neoadjuvant therapy for breast cancer. The primary endpoint is pathologic complete response (pCR, ypT0/is ypN0)). DNA repair deficiency in cancer cells can lead to immunogenic neoantigens, activation of the STING pathway, and PARP inhibition can also upregulate PD-L1 expression. Based on these rationales we tested the combination of durvalumab (anti-PDL1), olaparib (PARP inhibitor) and paclitaxel in I-SPY2. Methods: Women with tumors ≥ 2.5 cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment, hormone receptor positive (HR+) patients had to have MammaPrint high molecular profile. Treatment included durvalumab 1500 mg every 4 weeks x 3, olaparib 100 mg twice daily through weeks 1-11 concurrent with paclitaxel 80 mg/m2 weekly x 12 (DOP) followed by doxorubicin/cyclophosphamide (AC) x 4. The control arm was weekly paclitaxel x 12 followed by AC x 4. All patients undergo serial MRI imaging and imaging response at 3 & 12 weeks combined with accumulating pCR data are used to estimate, and continuously update, predicted pCR rate for the trial arm. Regimens “graduation with success” when the Bayesian predictive probability of success in a 300-patient phase 3 neoadjuvant trial in the appropriate biomarker groups reaches > 85%. Results: A total of 73 patients received DOP treatment including 21 HR- tumors (i.e. triple-negative breast cancer, TNBC) and 52 HR+ tumors between May 2018 - June 2019. The control group included 299 patients with HER2- tumors. The DOP arm graduated in June 2019, 13 months after enrollment had started, for all HER2- negative and the HR+/HER2- cohorts with > 0.85% predictive probabilities of success. 72 patient completed surgery and evaluable for pCR, the final predicted probabilities of success in a future phase III trial to demonstrate higher pCR rate with DOP compared to control are 81% for all HER2- cancers (estimated pCR rate 37%), 80% for TNBC (estimated pCR rate 47%) and 74.5% for HR+/HER2- patients (estimated pCR rate 28%). Association between pCR and germline BRCA status and immune gene expression including PDL1 will be presented at the meeting. No unexpected toxicities were seen, but 10 patients (14%) had possibly immune or olaparib related grade 2/3 AEs (3 pneumonitis, 2 adrenal insufficiency, 1 colitis, 1 pancreatitis, 2 elevated LFT, 1 skin toxicity, 2 hypothyroidism, 1 hyperthyroidism, 1 esophagitis). Conclusion: I-SPY2 demonstrated a significant improvement in pCR with durvalumab and olaparib included with paclitaxel compared to chemotherapy alone in women with stage II/III high-risk, HER2-negative breast cancer, improvement was seen in both the HR+ and TNBC subsets. Citation Format: Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT011.
Targeted Metagenomics for Clinical Detection and Discovery of Bacterial Tick-Borne Pathogens
Kingry, Luke C. , Sheldon, Sarah W., Oatman, Stephanie, Pritt, Bobbi S. , Anacker, Melissa , Bjork, Jenna , Neitzel, David F., Strain, Anna K., Berry, Jon, Sloan, Lynne M., Respicio-Kingry, Laurel, Dietrich, Elizabeth A. , Bloch, Karen C. , Moncayo, Abelardo C., Srinivasamoorthy, Ganesh, Hu, Bin , Mead, Paul S. , Petersen, Jeannine M., Kingry, Luke , Pritt, Bobbi, Sloan, Lynne, Pritt, Bobbi S , Berry, Jonathan, Hinckley, Alison F. , Kugeler, Kiersten J.

Mayo Clinic

Journal of Clinical Microbiology | September 1, 2020 | Volume: 58 | Issue: 11 | Pages: No page available

10.1128/jcm.00147-20 | PMID 32878950 Get It

Tick-borne diseases, due to a diversity of bacterial pathogens, represent a significant and increasing public health threat throughout the Northern Hemisphere. A high-throughput 16S V1-V2 rRNA gene-based metagenomics assay was developed and evaluated using >13,000 residual samples from patients suspected of having tick-borne illness and >1,000 controls. Taxonomic predictions for tick-borne bacteria were exceptionally accurate, as independently validated by secondary testing. Overall, 881 specimens were positive for bacterial tick-borne agents.
Cost-effectiveness of cardiovascular imaging for stable coronary heart disease
Walker, Simon , Cox, Edward , Rothwell, Ben , Berry, Colin , McCann, Gerry P , Bucciarelli‐Ducci, Chiara , Dall’Armellina, Erica , Prasad, Abhiram , Foley, James, Mangion, Kenneth , Bijsterveld, Petra , Everett, Colin , Stocken, Deborah , Plein, Sven , Greenwood, John P. , Sculpher, Mark , Bucciarelli-Ducci, Chiara , Plein, Sven , McCann, Gerry P , Walker, Simon , Greenwood, John P , Prasad, Abhiram , Berry, Colin , Cox, Edward

Mayo Clinic

Heart | August 14, 2020 | Volume: 107 | Issue: 5 | Pages: 381-388

10.1136/heartjnl-2020-316990 | PMID 32817271 Get It

Objective To assess the cost-effectiveness of management strategies for patients presenting with chest pain and suspected coronary heart disease (CHD): (1) cardiovascular magnetic resonance (CMR); (2) myocardial perfusion scintigraphy (MPS); and (3) UK National Institute for Health and Care Excellence (NICE) guideline-guided care. Methods Using UK data for 1202 patients from the Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2 trial, we conducted an economic evaluation to assess the cost-effectiveness of CMR, MPS and NICE guidelines. Health outcomes were expressed as quality-adjusted life-years (QALYs), and costs reflected UK pound sterling in 2016–2017. Cost-effectiveness results were presented as incremental cost-effectiveness ratios and incremental net health benefits overall and for low, medium and high pretest likelihood of CHD subgroups. Results CMR had the highest estimated QALY gain overall (2.21 (95% credible interval 2.15, 2.26) compared with 2.07 (1.92, 2.20) for NICE and 2.11 (2.01, 2.22) for MPS) and incurred comparable costs (overall £1625 (£1431, £1824) compared with £1753 (£1473, £2032) for NICE and £1768 (£1572, £1989) for MPS). Overall, CMR was the cost-effective strategy, being the dominant strategy (more effective, less costly) with incremental net health benefits per patient of 0.146 QALYs (−0.18, 0.406) compared with NICE guidelines at a cost-effectiveness threshold of £15 000 per QALY (93% probability of cost-effectiveness). Results were similar in the pretest likelihood subgroups. Conclusions CMR-guided care is cost-effective overall and across all pretest likelihood subgroups, compared with MPS and NICE guidelines.
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Yee, Douglas , Symmans, W. Fraser , Albain, Kathy S. , Chen, Yunn-Yi, Krings, Gregor , Wei, Shi , Harada, Shuko , Datnow, Brian, Fadare, Oluwole , Klein, Molly, Chen, Beiyun, Adamson, Kathi, Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Magliocco, Anthony M., Feldman, Mike, Rendi, Mara H. , Sattar, Husain, Zeck, Jay , Ocal, Idris Tolgay, Tawfik, Ossama , LeBeau, Lauren, Sahoo, Sunati , Vinh, Tuyethoa N., Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Lu, Janice , Lang, Julie E. , Clark, Amy S. , Nanda, Rita , Northfelt, Donald W. , Khan, Qamar J. , Viscusi, Rebecca K., Euhus, David , Edmiston, Kirsten K., Kemmer, Kathleen, Park, John W., Liu, Minetta C. , Olopade, Olufunmilayo I. , Leyland‐Jones, Brian , Tripathy, Debasish , Moulder, Stacy L. , Schwab, Richard B. , Lo, Shelly S. , Beckwith, Heather , Haugen, Patricia, Veer, Laura J. van’t , Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Hirst, Gillian L. , Singhrao, Ruby , Steeg, Katherine, Matthews, Jeffrey B. , Asare, Smita , Sanil, Ashish, Esserman, Laura J. , Berry, Donald A. , Tripathy, Debu , Ocal, Idris T, Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , DeMichele, Angela , Yau, Christina , Isaacs, Claudine , Chen, Yunn‐Yi , Krings, Gregor, Pambuccian, Stefan E. , Wallace, Anne M. , Pusztai, Lajos , Boughey, Judy C. , Elias, Anthony , Han, Hyo S , Chui, Stephen Y., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Asare, Adam L. , Matthews, Jeffrey B., Berry, Scott

Mayo Clinic

JAMA Oncology | July 23, 2020 | Volume: 6 | Issue: 9 | Pages: 1355

10.1001/jamaoncol.2020.2535 | PMID 32701140 Get It

Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis
Karau, Melissa J. , Schmidt-Malan, Suzannah M., Albano, Mariana , Mandrekar, Jayawant N. , Rivera, Christina G. , Osmon, Douglas R. , Oravec, Caitlin P., Berry, Daniel J. , Patel, Robin , Patel, Robin , Berry, Daniel J , Rivera, Christina G , Abdel, Matthew P.

Mayo Clinic

The Journal of Infectious Diseases | July 5, 2020 | Volume: 222 | Issue: 9 | Pages: 1498-1504

10.1093/infdis/jiaa401 | PMID 32914837 Get It

Abstract Background Owing to patient intolerance or drug interactions, alternative agents to rifampin are needed for management of staphylococcal periprosthetic joint infection. In the current study, we evaluated rifabutin, rifapentine and rifampin, with and without vancomycin, in a rat model of foreign body osteomyelitis. Methods Proximal tibiae were inoculated with methicillin-resistant Staphylococcus aureus (MRSA) and a Kirschner wire (K-wire) implanted in each. After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, alone or with vancomycin. Tibiae and K-wires were cultured, and medians were reported as log10 colony-forming units (CFUs) per gram of bone or log10 CFUs per K-wire, respectively. Results Rifampin, rifabutin or rifapentine administered with vancomycin yielded less MRSA from bones (0.10, 3.02, and 0.10 log10 CFUs/g, respectively) than did no treatment (4.36 log10 CFUs/g) or vancomycin alone (4.64 log10 CFUs/g) (both P ≤ .02). The K-wires of animals receiving no treatment or vancomycin monotherapy recovered medians of 1.76 and 2.91 log10 CFUs/g per K-wire, respectively. In contrast, rifampin, rifabutin and rifapentine administered with vancomycin yielded medians of 0.1 log10 CFUs per K-wire, respectively. Rifampin resistance was detected in a single animal in the rifampin monotherapy group. Conclusions Rifabutin or rifapentine with vancomycin were as active as rifampin with vancomycin against MRSA in rat foreign body osteomyelitis, suggesting that rifabutin and/or rifapentine may be alternatives to rifampin in the clinical management of staphylococcal periprosthetic joint infections.
Trends in the use of dual mobility bearings in hip arthroplasty
Heckmann, Nathanael D. , Weitzman, Dena S., Jaffri, Heena, Berry, Daniel J. , Springer, Bryan D. , Lieberman, Jay R. , Heckmann, Nathanael , Berry, Daniel J

Mayo Clinic

The Bone & Joint Journal | June 30, 2020 | Volume: 102-B | Issue: 7_Supple_B | Pages: 27-32

10.1302/0301-620x.102b7.bjj-2019-1669.r1 | PMID 32600197 Get It

Aims Dual mobility (DM) bearings are an attractive treatment option to obtain hip stability during challenging primary and revision total hip arthroplasty (THA) cases. The purpose of this study was to analyze data submitted to the American Joint Replacement Registry (AJRR) to characterize utilization trends of DM bearings in the USA. Methods All primary and revision THA procedures reported to AJRR from 2012 to 2018 were analyzed. Patients of all ages were included and subdivided into DM and traditional bearing surface cohorts. Patient demographics, geographical region, hospital size, and teaching affiliation were assessed. Associations were determined by chi-squared analysis and logistic regression was performed to assess outcome variables. Results A total of 406,900 primary and 34,745 revision THAs were identified, of which 35,455 (8.7%) and 8,031 (23.1%) received DM implants respectively. For primary THA, DM usage increased from 6.7% in 2012 to 12.0% in 2018. Among revision THA, DM use increased from 19.5% in 2012 to 30.6% in 2018. Patients < 50 years of age had the highest rates of DM implantation in every year examined. For each year of increase in age, there was a 0.4% decrease in the rate of DM utilization (odds ratio (OR) 0.996 (95% confidence interval (CI) 0.995 to 0.997); p < 0.001). Females were more likely to receive a DM implant compared to males (OR 1.077 (95% CI 1.054 to 1.100); p < 0.001). Major teaching institutions and smaller hospitals were associated with higher rates of utilization. DM articulations were used more commonly for dysplasia compared with osteoarthritis (OR 2.448 (95% CI 2.032 to 2.949); p < 0.001) during primary THA and for instability (OR 3.130 (95% CI 2.751 to 3.562) vs poly-wear; p < 0.001) in the revision setting. Conclusion DM articulations showed a marked increase in utilization during the period examined. Younger patient age, female sex, and hospital characteristics such as teaching status, smaller size, and geographical location were associated with increased utilization. DM articulations were used more frequently for primary THA in patients with dysplasia and for revision THA in patients being treated for instability. Cite this article: Bone Joint J 2020;102-B(7 Supple B):27–32.
Anti-fibrotic effects of the antihistamine ketotifen in a rabbit model of arthrofibrosis
Tibbo, Meagan E. , Limberg, Afton K. , Salib, Christopher G. , Turner, Travis W., McLaury, Alex R., Bettencourt, Jacob W. , Carter, Jodi M. , Berry, Daniel J, Wijnen, André J. van , Berry, Daniel J. , Jay, Anthony G. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Berry, Daniel J , Carter, Jodi , Bolon, Brad , Berry, Daniel J, Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | June 17, 2020 | Volume: 9 | Issue: 6 | Pages: 302-310

10.1302/2046-3758.96.bjr-2019-0272.r2 | PMID 32728431 Get It

Aims Arthrofibrosis is a relatively common complication after joint injuries and surgery, particularly in the knee. The present study used a previously described and validated rabbit model to assess the biomechanical, histopathological, and molecular effects of the mast cell stabilizer ketotifen on surgically induced knee joint contractures in female rabbits. Methods A group of 12 skeletally mature rabbits were randomly divided into two groups. One group received subcutaneous (SQ) saline, and a second group received SQ ketotifen injections. Biomechanical data were collected at eight, ten, 16, and 24 weeks. At the time of necropsy, posterior capsule tissue was collected for histopathological and gene expression analyses (messenger RNA (mRNA) and protein). Results At the 24-week timepoint, there was a statistically significant increase in passive extension among rabbits treated with ketotifen compared to those treated with saline (p = 0.03). However, no difference in capsular stiffness was detected. Histopathological data failed to demonstrate a decrease in the density of fibrous tissue or a decrease in α-smooth muscle actin (α-SMA) staining with ketotifen treatment. In contrast, tryptase and α-SMA protein expression in the ketotifen group were decreased when compared to saline controls (p = 0.007 and p = 0.01, respectively). Furthermore, there was a significant decrease in α-SMA (ACTA2) gene expression in the ketotifen group compared to the control group (p < 0.001). Conclusion Collectively, these data suggest that ketotifen mitigates the severity of contracture formation in a rabbit model of arthrofibrosis. Cite this article: Bone Joint Res 2020;9(6):302–310.